Search Results

• • 19 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.

  Authors:Philippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, et al.From:The Lancet (Vol. 397, Issue 10292) Peer-Reviewed

  June 19, 2021883 words Report

   Abstract Only

• High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma

  Authors:Normann Steiner, Roman Hajek, Sabina Sevcikova, Bojana Borjan, Karin Johrer, Georg Gobel, et al.From:PLoS ONE (Vol. 12, Issue 7) Peer-Reviewed

  July 20, 20174,819 words Report 1390LIntroduction Multiple myeloma (MM) is still incurable due to resistance against various therapies. Thus, the identification of biomarkers predicting progression is urgently needed. Here, we evaluated four biomarkers...

• Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma

  Authors:Karthick Raja Muthu Raja, Lucie Rihova, Lenka Zahradova, Maria Klincova, Miroslav Penka, and Roman HajekFrom:PLoS ONE (Vol. 7, Issue 10) Peer-Reviewed

  Oct. 10, 20127,118 words Article 1480LBackground Regulatory T (Treg) cells play an important role in the maintenance of immune system homeostasis. Multiple myeloma (MM) is a plasma cell disorder frequently associated with impaired immune cell numbers and...

• Continuous Lenalidomide treatment for newly diagnosed multiple myeloma

  Authors:Antonio Palumbo, Roman Hajek, Michel Delforge, Martin Kropff, Maria Teresa Petrucci, John Catalano, et al.From:The New England Journal of Medicine (Vol. 366, Issue 19) Peer-Reviewed

  May 10, 201241 words Clinical report

   Citation Only

• Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

  Authors:Steven Horwitz, Owen A O'Connor, Barbara Pro, Tim Illidge, Michelle Fanale, Ranjana Advani, et al.From:The Lancet (Vol. 393, Issue 10168) Peer-Reviewed

  Jan. 19, 20191,192 words Article

   Abstract Only

• Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

  Authors:Sebastian Grosicki, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryrna Kriachok, Maria Gavriatopoulou, et al.From:The Lancet (Vol. 396, Issue 10262) Peer-Reviewed

  Nov. 14, 20201,296 words Article

   Abstract Only

• Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-[alpha] administration

  Authors:Roman Hajek, Daniela Zackova, Tomas Buchler, Miroslav Penka, Eva Krahulcova, Zdenek KorAstek, et al.From:Medical Oncology (Vol. 20, Issue 1) Peer-Reviewed

  Mar. 2003384 words Article

   Abstract Only

• Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience

  Authors:Jan Smetana, Jan Frohlich, Romana Zaoralova, Vladimira Vallova, Henrieta Greslikova, Renata Kupska, et al.From:BioMed Research InternationalPeer-Reviewed

  Annual 20146,285 words Report 1410LCharacteristic recurrent copy number aberrations (CNAs) play a key role in multiple myeloma (MM) pathogenesis and have important prognostic significance for MM patients. Array-based comparative genomic hybridization...

• Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy

  Authors:Jiri Minarik, Petr Pavlicek, Ludek Pour, Tomas Pika, Vladimir Maisnar, Ivan Spicka, et al.From:PLoS ONE (Vol. 10, Issue 4) Peer-Reviewed

  Apr. 14, 20154,797 words Article 1620LObjective Subcutaneous (SC) application of bortezomib has been recently introduced as a new application route in multiple myeloma (MM) patients. We performed an analysis to compare the outcomes of bortezomib-based...

• Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma

  Authors:Lenka Besse, Lenka Sedlarikova, Fedor Kryukov, Jana Nekvindova, Lenka Radova, Ondrej Slaby, et al.From:PLoS ONE (Vol. 10, Issue 9) Peer-Reviewed

  Sept. 21, 20155,084 words Report 1520LPoor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA distinguishing...

• Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

  Authors:Maria V. Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hájek, et al.From:Journal of Hematology & Oncology (Vol. 14, Issue 1) Peer-Reviewed

  Apr. 13, 20212,085 words Clinical report 1740LTherapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with...

• Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

  Authors:Meletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, et al.From:The Lancet (Vol. 393, Issue 10168) Peer-Reviewed

  Jan. 19, 20191,264 words Article

   Abstract Only

• Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

  Authors:A Keith Stewart, Tamas Masszi, Ivan Spicka, Xinqun Yang, Naseem Zojwalla, Maria-Victoria Mateos, et al.From:The New England Journal of Medicine (Vol. 372, Issue 2) Peer-Reviewed

  Jan. 8, 201567 words Report

   Citation Only

• Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

  Authors:Pieter Sonneveld, Roman Hajek, Arnon Nagler, Andrew Spencer, Joan Blade, Tadeusz Robak, et al.From:Cancer (Vol. 112, Issue 7) Peer-Reviewed

  Apr. 1, 2008 Clinical report

   Citation Only

• Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

  Authors:Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Andrew H. Wei, et al.From:The New England Journal of Medicine (Vol. 383, Issue 7) Peer-Reviewed

  Aug. 13, 202036 words Clinical report

   Citation Only

• Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment

  Authors:Karthick Raja Muthu Raja, Lenka Kubiczkova, Lucie Rihova, Martin Piskacek, Pavla Vsianska, Renata Hezova, et al.From:PLoS ONE (Vol. 7, Issue 11) Peer-Reviewed

  Nov. 13, 20125,738 words Article 1390LAuthor(s): Karthick Raja Muthu Raja 1 , 2 , * , Lenka Kubiczkova 1 , Lucie Rihova 1 , 3 , Martin Piskacek 1 , Pavla Vsianska 2 , 3 , Renata Hezova 5 , Ludek Pour 4 , Roman Hajek 1 , 2 , 3 , 4 Introduction Multiple...

• Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

  Authors:Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Blade, Roman Hajek, Andrew Spencer, et al.From:Cancer (Vol. 122, Issue 13) Peer-Reviewed

  July 1, 2016 Report

   Citation Only

• Dendritic cell vaccines in the treatment of multiple myeloma; Advances and limitations

  Authors:Tomas Buchler and Roman HajekFrom:Medical Oncology (Vol. 19, Issue 4) Peer-Reviewed

  Dec. 2002183 words Article

   Abstract Only

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

  Authors:Michel Attal, Paul G Richardson, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, et al.From:The Lancet (Vol. 394, Issue 10214) Peer-Reviewed

  Dec. 7, 20191,124 words Report

   Abstract Only